Enlivex Therapeutics (NASDAQ:ENLV) Receives “Buy” Rating from D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Enlivex Therapeutics (NASDAQ:ENLV) in a report released on Tuesday morning,Benzinga reports. D. Boral Capital currently has a $13.00 price objective on the stock.

Several other research firms have also recently weighed in on ENLV. EF Hutton Acquisition Co. I upgraded Enlivex Therapeutics to a “strong-buy” rating in a research note on Tuesday, August 27th. HC Wainwright restated a “buy” rating and issued a $6.00 target price on shares of Enlivex Therapeutics in a report on Friday, September 27th.

Enlivex Therapeutics Price Performance

NASDAQ:ENLV opened at $1.30 on Tuesday. Enlivex Therapeutics has a 12 month low of $0.81 and a 12 month high of $4.59. The firm has a market capitalization of $27.83 million, a PE ratio of -1.33 and a beta of 1.01. The business’s fifty day moving average price is $1.35 and its 200 day moving average price is $1.35.

Institutional Investors Weigh In On Enlivex Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. XTX Topco Ltd acquired a new position in shares of Enlivex Therapeutics in the 2nd quarter valued at $35,000. Sigma Investment Counselors Inc. acquired a new position in Enlivex Therapeutics in the third quarter valued at $50,000. Finally, Armistice Capital LLC purchased a new stake in shares of Enlivex Therapeutics in the second quarter valued at about $2,415,000. Hedge funds and other institutional investors own 1.02% of the company’s stock.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.